S

SELLAS Life Sciences Group
D

SLS

1.45000
USD
0.02
(1.05%)
قبل الجلسة
حجم التداول
100
الربح لكل سهم
-3
العائد الربحي
-
P/E
-5
حجم السوق
206,541,247
أصول ذات صلة الأخبار المقالات

العنوان: SELLAS Life Sciences Group

القطاع: Healthcare
الصناعة: Biotechnology
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.